Nasus Pharma Ltd. (NSRX)

Nasus Pharma Statistics

Total Valuation

Nasus Pharma has a market cap or net worth of $63.42 million. The enterprise value is $62.67 million.

Market Cap	63.42M
Enterprise Value	62.67M

Important Dates

The next estimated earnings date is Tuesday, December 2, 2025, before market open.

Earnings Date	Dec 2, 2025
Ex-Dividend Date	n/a

Share Statistics

Nasus Pharma has 9.06 million shares outstanding. The number of shares has decreased by -0.43% in one year.

Current Share Class	9.06M
Shares Outstanding	9.06M
Shares Change (YoY)	-0.43%
Shares Change (QoQ)	+4.01%
Owned by Insiders (%)	43.73%
Owned by Institutions (%)	0.04%
Float	2.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.12

Current Ratio	0.12
Quick Ratio	0.10
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-37.17

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-116.06%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	33.56%
Revenue Per Employee	n/a
Profits Per Employee	-$766,000
Employee Count	2
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	7.63
200-Day Moving Average	n/a
Relative Strength Index (RSI)	41.49
Average Volume (20 Days)	3,324

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-1.08M
Pretax Income	-1.55M
Net Income	-1.53M
EBITDA	n/a
EBIT	-1.08M
Earnings Per Share (EPS)	-$0.22

Balance Sheet

The company has $284,000 in cash and $1.80 million in debt, giving a net cash position of -$1.52 million or -$0.17 per share.

Cash & Cash Equivalents	284,000
Total Debt	1.80M
Net Cash	-1.52M
Net Cash Per Share	-$0.17
Equity (Book Value)	-3.21M
Book Value Per Share	-0.44
Working Capital	-3.47M

Cash Flow

Operating Cash Flow	-665,000
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Nasus Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.43%
Shareholder Yield	0.43%
Earnings Yield	-2.51%
FCF Yield	n/a

Analyst Forecast

The average price target for Nasus Pharma is $22.00, which is 214.29% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$22.00
Price Target Difference	214.29%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2